Top Markets
#1 QuantixAI QuantixAI +105.36%
#2 龙虾 (Lobster) 龙虾 (Lobster) +67.63%
#3 Pons Pons +30.61%
#4 MetaDAO MetaDAO +27.67%
#5 Rain Rain +23.05%
#6 Bedrock Bedrock +21.57%
#7 Ontology Gas Ontology Gas +17.29%
#8 Prom Prom +16.07%
#9 Humanity Humanity +14.61%
#10 Stacks Stacks +14.02%
Coin of the day
QuantixAI QuantixAI
Settings
Language
ENGLISH
Currency
USD
Theme
CG Oncology Inc. CG Oncology Inc.

CG Oncology Inc.

CGON
Rank in Stocks #2843
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops... CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC. It also develops cretostimogene monotherapy for intermediate-risk NMIBC following TURBT, which is in phase 3 PIVOT-006 clinical trials to assess the safety and efficacy of adjuvant cretostimogene; and cretostimogene monotherapy for high-risk NMIBC in phase 2 CORE-008 clinical trials to assess the safety and clinical outcomes of cretostimogene in treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC. The company was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. CG Oncology, Inc. was founded in 2010 and is headquartered in Irvine, California.
Share Price
$78.86
Market Cap
$6.96B
Change (1 day)
0.80%
Change (1 year)
210.23%
Country
US
Trade CG Oncology Inc. (CGON)

Category

Healthcare
Number of shares outstanding for CG Oncology Inc. (CGON)
Number of shares outstanding as of August 2026: 0
According to CG Oncology Inc. latest financial reports and stock price the company's current number of shares outstanding is 0. At the end of August 2026 the company had 0 shares outstanding. The number of outstanding shares is usually impacted by stock plits and shares buy back.
Shares outstanding history for CG Oncology Inc. (CGON) from 2026 to 2026
Shares Outstanding at the end of each year
Year Shares Outstanding Change
Not enough data for the provided dates.
Shares Outstanding for similar companies or competitors
Company Shares Outstanding Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 253.90M -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 62.19M -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 396.00M -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 478.91M -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH